Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA (R) (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP.

Trial Profile

Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA (R) (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Apr 2015

At a glance

  • Drugs Fondaparinux sodium (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 02 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top